所有图片(1)
别名:
IDN-6556, N-[2-(1,1-dimethylethyl)phenyl]-2-oxoglycyl-N-[(1S)-1-(carboxymethyl)-2-oxo-3-(2,3,5,6-tetrafluorophenoxy)propyl]-L-Alaninamide, PF-03491390
经验公式（希尔记法）:
C26H27F4N3O7
推荐产品
检测方案
≥98% (HPLC)
形式
powder
颜色
white to beige
溶解性
DMSO: 2 mg/mL, clear
运输
wet ice
储存温度
−20°C
SMILES字符串
CC(C)(C)C1=C(NC(C(N[C@@H](C)C(N[C@@H](CC(O)=O)C(COC2=C(F)C(F)=CC(F)=C2F)=O)=O)=O)=O)C=CC=C1
InChI
1S/C26H27F4N3O7/c1-12(31-24(38)25(39)32-16-8-6-5-7-13(16)26(2,3)4)23(37)33-17(10-19(35)36)18(34)11-40-22-20(29)14(27)9-15(28)21(22)30/h5-9,12,17H,10-11H2,1-4H3,(H,31,38)(H,32,39)(H,33,37)(H,35,36)/t12-,17-/m0/s1
InChI key
SCVHJVCATBPIHN-SJCJKPOMSA-N
生化/生理作用
Emricasan is an antiapoptotic pan-caspase inhibitor. It has been in clinical trials for the treatment of non-alcoholic steatohepatitis (NASH) with advanced fibrosis (scarring) and cirrhosis. Emricasan has also been shown to protect infected astrocytes from ZIKV-induced cell death.
Emricasan, formerly known as IDN-6556, in combination with birinapan is used to treat acute myeloid leukemia (AML). This small molecule irreversible inhibitor is under clinical investigation to reduce hepatic injury and liver fibrosis.
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
Carcinogenicity assessment of the pan-caspase inhibitor, emricasan, in Tg.rasH2 mice
Elbekai RH, et al.
Regulatory Toxicology and Pharmacology, 72, 169-178 (2015)
The caspase-8 inhibitor emricasan combines with the SMAC mimetic birinapant to induce necroptosis and treat acute myeloid leukemia
Brumatti G, et al.
Science Translational Medicine, 8, 339ra69-339ra69 (2016)
Haiyan Zhang et al.
Frontiers in cardiovascular medicine, 8, 685434-685434 (2021-08-03)
Dexrazoxane (DXZ) reduces cytotoxicity caused by Doxorubicin (DOX). However, the mechanism of DXZ in ferroptosis and cardiomyopathy remains unclear. This research, therefore, explores the role and mechanism of DXZ in DOX-induced ferroptosis and cardiomyopathy in rats. Kaplan-Meier survival analysis was
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门